Journal
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
Volume 8, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fbioe.2020.00997
Keywords
mesenchymal stem cells; extracellular vesicles; regenerative medicine; therapy; clinical translation
Funding
- Inserm Institute [ANR-11-INSB-005]
- University of Montpellier [ANR-11-INSB-005]
- Agence Nationale de la Recherche [ANR-11-INSB-005]
- FOREUM Foundation for Research in Rheumatology
Ask authors/readers for more resources
Extracellular vesicles (EVs), including exosomes and microvesicles, derived from mesenchymal stem/stromal cells (MSCs) exert similar effects as their parental cells, and are of interest for various therapeutic applications. EVs can act through uptake by the target cells followed by release of their cargo inside the cytoplasm, or through interaction of membrane-bound ligands with receptors expressed on target cells to stimulate downstream intracellular pathways. EV-based therapeutics may be directly used as substitutes of intact cells or after modification for targeted drug delivery. However, for the development of EV-based therapeutics, several production, isolation, and characterization requirements have to be met and the quality of the final product has to be tested before its clinical implementation. In this review, we discuss the challenges associated with the development of EV-based therapeutics and the regulatory specifications for their successful clinical translation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available